PDCD1 and glioma: In combination with the immune checkpoint inhibitor, αPD-1, CCR2 antagonism unmasked an effect of PD-1 blockade in slowing the tumor progression of two immune checkpoint inhibitor-resistant murine gliomas (KR158B and 005 GSC) (28).